CELLSFORCELLS (C4C)

Cell-free therapy based on exosomes is witnessing a surge of published scientific papers, a rise of IP and registered clinicals trials, all driven by a swelling avidity among investors to support this transformative nanomedicine approach.

For cell-free treatment to become a reality, they need to overcome the many manufacturing hurdles posed by the large-scale production of purified exosomes.
Cells for Cells, a clinical-stage biotech company, has announced the publication of new data of its OxiumTMEXO cell culture media for increased exosome production in Frontiers in Biotechnology and Bioengineering, a specialized journal of the field. The company is part of REGENERO, the Chilean consortium for regenerative medicine supported by state funding (CORFO). In a head-to-head comparison, OxiumTMEXO outmatched the standard DMEM (starvation protocol) and a commercially available medium for exosome production. OxiumTMEXO allowed different type of cells, including the broadly used mesenchymal stem cells, to increase by 3-folds their particle production. The isolated exosomes expressed the typical pan markers while preserving their functionality both in vitro and in vivo.

CELLSFORCELLS (C4C)

Home

Videos

Playlists

About

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.